Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263715 | 0.84 | HDAC6 (0.59) | KDM4EALDH1A1LMNATMPRSS2TAAR1 | |
| SCHEMBL3095946 | 0.83 | HPGD (0.71) | MYCSMN1; SMN2HPGDKDM4EALOX15 | |
| SCHEMBL6618191 | 0.83 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTPOLBKMT2A | |
| SCHEMBL27478801 | 0.82 | ALDH1A1 (0.46) | MYCSMN1; SMN2HPGDKDM4EALOX15 | |
| SCHEMBL3281765 | 0.82 | MYC (0.49) | MYCSMN1; SMN2HPGDKDM4EALOX15 | |
| SCHEMBL6619460 | 0.82 | ALDH1A1 (0.48) | HPGDPTGDRPTGDR2PTGER2CYP2C9 | |
| SCHEMBL3281279 | 0.81 | MYC (0.58) | MYCSMN1; SMN2HPGDKDM4EALDH1A1 | |
| SCHEMBL3286985 | 0.81 | CYP2C9 (0.49) | MYCKDM4EPTGDR2CYP2C9POLB | |
| SCHEMBL1263079 | 0.80 | HDAC6 (0.66) | ALDH1A1LMNATMPRSS2 | |
| SCHEMBL3281507 | 0.79 | HDAC6 (0.69) | MYCSMN1; SMN2HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | MYC 4493/4885SMN1; SMN2 88/4885HPGD 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.